Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052085 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL756618 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL5051917 | 1.00 | LMNA (0.59) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL521727 | 0.94 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL5133813 | 0.94 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL10620808 | 0.94 | LMNA (0.69) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL20239632 | 0.87 | LMNA (0.39) | LMNAL3MBTL1TDP1ALDH1A1NR1I2 | |
| Xylitol SCHEMBL4599492 | 0.83 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL5273838 | 0.83 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Adonitol SCHEMBL20594035 | 0.83 | LMNA (0.83) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389565-B2 | Antidiabetic agents; controlling carbohydrate metabolism | SIMON FRASER UNIVERSITY (CA) | 2013-03-05 | — | — | US | disclosed |
| EP-1999124-A1 | GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007098597-A1 | GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2007-09-07 | — | — | WO | disclosed |
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | SIMON FRASER UNIVERSITY (CA) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247222-A1 | Glycosidase inhibitors and methods of synthesizing same | STS, SCLY, MGAM | LMNA 4251/4885L3MBTL1 2189/4885TDP1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.